Moderna Therapeutics

article

Pharmaceutical C-suite update

21 June 2022 | By Hannah Balfour (European Pharmaceutical Review)

With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.

article

New year, new cell and gene therapy collaborations

11 January 2022 | By Hannah Balfour (European Pharmaceutical Review)

Here we run down four new research collaborations in the cell and gene therapy sector, announced by Bayer, BMS, Pfizer and Moderna.

news

mRNA vaccine for Epstein-Barr Virus enters Phase I trial

6 January 2022 | By Hannah Balfour (European Pharmaceutical Review)

The first patient dosed in Phase I study of Moderna’s mRNA-1189, a vaccine candidate for Epstein-Barr Virus (EBV).

article

Who will receive COVID-19 vaccines first?

12 October 2020 | By Hannah Balfour (European Pharmaceutical Review)

EPR’s Hannah Balfour discusses some of the proposed COVID-19 vaccine distribution plans and how medicinal nationalism and supply deals could prevent “fair and equitable access” to COVID-19 vaccines.

news

Biopharma pledges to uphold scientific integrity in COVID-19 vaccine development

9 September 2020 | By Hannah Balfour (European Pharmaceutical Review)

Nine biopharma CEOs pledged to make the integrity of the scientific process and sufficient supply priorities in the development of COVID-19 vaccines.

news

Experimental COVID-19 vaccine mRNA-1273 is safe and elicits response

15 July 2020 | By Hannah Balfour (European Pharmaceutical Review)

Interim analysis of the Phase I trial data from 45 patients indicates mRNA-1273 can drive the production of antibodies targeting the SARS-CoV-2 spike protein.

article

COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?

10 April 2020 | By Victoria Rees (European Pharmaceutical Review)

A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.